These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

460 related items for PubMed ID: 17989604

  • 41. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
    Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, Robertson M, Ford I, SHIFT Investigators.
    Int J Cardiol; 2013 Dec 10; 170(2):182-8. PubMed ID: 24225201
    [Abstract] [Full Text] [Related]

  • 42. Treatment of stable angina pectoris by ivabradine in every day practice: the REDUCTION study.
    Köster R, Kaehler J, Meinertz T, REDUCTION Study Group.
    Am Heart J; 2009 Oct 10; 158(4):e51-7. PubMed ID: 19781403
    [Abstract] [Full Text] [Related]

  • 43. [Heart rate control: f-channel blockers].
    Kryzhanovskiĭ SA, Vititnova MB.
    Fiziol Cheloveka; 2009 Oct 10; 35(2):112-23. PubMed ID: 19402561
    [No Abstract] [Full Text] [Related]

  • 44. Five-year results of heart rate control with ivabradine or metoprolol succinate in patients after heart transplantation.
    Rivinius R, Helmschrott M, Rahm AK, Darche FF, Thomas D, Bruckner T, Doesch AO, Katus HA, Ehlermann P.
    Clin Res Cardiol; 2022 Feb 10; 111(2):141-153. PubMed ID: 32572551
    [Abstract] [Full Text] [Related]

  • 45. Effect of graded heart rate reduction with ivabradine on myocardial oxygen consumption and diastolic time in exercising dogs.
    Colin P, Ghaleh B, Monnet X, Hittinger L, Berdeaux A.
    J Pharmacol Exp Ther; 2004 Jan 10; 308(1):236-40. PubMed ID: 14569053
    [Abstract] [Full Text] [Related]

  • 46. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study.
    Doesch AO, Mueller S, Erbel C, Gleissner CA, Frankenstein L, Hardt S, Ruhparwar A, Ehlermann P, Dengler T, Katus HA.
    Drug Des Devel Ther; 2013 Jan 10; 7():1323-8. PubMed ID: 24235815
    [Abstract] [Full Text] [Related]

  • 47. Ivabradine: A Unique and Intriguing Medication for Treating Cardiovascular Disease.
    Nawarskas JJ, Bowman BN, Anderson JR.
    Cardiol Rev; 2015 Jan 10; 23(4):201-11. PubMed ID: 25839989
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis.
    Schirmer SH, Degen A, Baumhäkel M, Custodis F, Schuh L, Kohlhaas M, Friedrich E, Bahlmann F, Kappl R, Maack C, Böhm M, Laufs U.
    Eur Heart J; 2012 May 10; 33(10):1223-31. PubMed ID: 21821843
    [Abstract] [Full Text] [Related]

  • 50. Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study.
    Zhang R, Bobylev D, Stiefel P, Haverich A, Bara C.
    Clin Res Cardiol; 2012 Aug 10; 101(8):631-6. PubMed ID: 22391988
    [Abstract] [Full Text] [Related]

  • 51. Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients.
    Nerla R, Di Franco A, Milo M, Pitocco D, Zaccardi F, Tarzia P, Sarullo FM, Villano A, Russo G, Stazi A, Ghirlanda G, Lanza GA, Crea F.
    Heart; 2012 Dec 10; 98(24):1812-6. PubMed ID: 23086971
    [Abstract] [Full Text] [Related]

  • 52. Ivabradine, a novel heart rate slower: is it a sword of double blades in patients with idiopathic dilated cardiomyopathy?
    Rayan M, Tawfik M, Alabd A, Gamal A.
    Anadolu Kardiyol Derg; 2011 Aug 10; 11(5):402-6. PubMed ID: 21712169
    [Abstract] [Full Text] [Related]

  • 53. Ivabradine versus metoprolol for heart rate reduction before coronary computed tomography angiography.
    Pichler P, Pichler-Cetin E, Vertesich M, Mendel H, Sochor H, Dock W, Syeda B.
    Am J Cardiol; 2012 Jan 15; 109(2):169-73. PubMed ID: 22011557
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010 Jan 15; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Drug insight: If inhibitors as specific heart-rate-reducing agents.
    Borer JS.
    Nat Clin Pract Cardiovasc Med; 2004 Dec 15; 1(2):103-9. PubMed ID: 16265314
    [Abstract] [Full Text] [Related]

  • 58. Cardioprotection by ivabradine through heart rate reduction and beyond.
    Heusch G, Skyschally A, Schulz R.
    J Cardiovasc Pharmacol Ther; 2011 Dec 15; 16(3-4):281-4. PubMed ID: 21821529
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.